| Document |
Document Title |
|
WO/2024/059740A1 |
Provided herein are polynucleotides and genetically modified cells comprising polynucleotides encoding a genetically modified major histocompatibility complex (MHC) associated polypeptide linked to an adapter peptide that is capable of b...
|
|
WO/2024/056560A1 |
The present invention relates to a recombinant expression vector encoding an inducible cell death switch, a pH-stable fluorophore and a pH-sensitive fluorophore. Moreover, the invention relates to cells comprising said recombinant expres...
|
|
WO/2024/059812A2 |
Tissue modulating systems, devices, and methods modulate and/or stimulate numerous tissue specimens, independently and in parallel, within a multi-well plate in such a way to allow simultaneous measurement of functional properties of the...
|
|
WO/2024/055995A1 |
Provided are an anti-VEGFA fusion protein, and a preparation method therefor and the use thereof. The anti-VEGFA fusion protein has a high affinity with VEGFA, can effectively block the binding of VEGFA to receptor VEGFR, block a VEGFA s...
|
|
WO/2024/055339A1 |
Provided are a genetically engineered feeder cell expressing CD19 and at least one molecule that stimulates immune cell activation, a method for preparing the genetically engineered feeder cell, and use of the genetically engineered feed...
|
|
WO/2024/059252A2 |
An ECM-embedded vascular channel-on-a-chip includes an outer case having an internal chamber, an ECM provided within the chamber, the ECM having a cross-sectionally rounded vascular channel having a first end and a second end opposite th...
|
|
WO/2024/056098A1 |
Provided are an NK cell adapter molecule targeting an NKG2D ligand and an NKp46 and the use thereof. The cell adapter molecule at least comprises: a first binding domain comprising an NKG2D extracellular domain that can specifically bind...
|
|
WO/2024/059584A1 |
In various aspects, the invention provides culture platforms, cell media, and methods of differentiating pluripotent cells into hematopoietic cells. In certain aspects, the invention further provides pluripotent stem cell-derived hematop...
|
|
WO/2024/059712A1 |
Disclosed herein are non-viral methods to ablate Activating transcription factor 6 (ATF6), X-box binding protein 1 (XBP1), and/or protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) in T cells while effectively expressing chi...
|
|
WO/2024/058679A1 |
The first object of the invention is a fibrin patch containing corneal limbal epithelial cells, characterized in that it contains a protein substrate, which is dried and rehydrated fibrin, a density of corneal limbal epithelial cells on ...
|
|
WO/2024/056601A1 |
The invention relates to devices for measuring cellular avidity and to processes for making and using the devices.
|
|
WO/2024/052563A1 |
The present invention relates to the protein myeloid-derived growth factor (MYDGF) or nucleic acids encoding said protein for use in treating and/or preventing cardiogenic shock. The present invention also relates to vectors comprising t...
|
|
WO/2024/052433A1 |
The invention relates to tissue-imprinting molecular program and the associated T cell progenitors in tumors and draining lymph nodes and their therapeutic application.
|
|
WO/2024/052564A1 |
The present invention relates to the protein myeloid-derived growth factor (MYDGF) or nucleic acids encoding said protein for use in treating and/or preventing cardiogenic shock. The present invention also relates to vectors comprising t...
|
|
WO/2024/052919A1 |
The present invention provides polynucleotide sequences derived from Helichrysum umbraculigerum and encoding a protein or a plurality thereof belonging to the polyketide synthase (PKS) family. Further provided are an artificial nucleic a...
|
|
WO/2024/053630A1 |
The present disclosure provides a new carrier peptide fragment having cell membrane permeability. The disclosed carrier peptide fragment comprises the following amino acid sequence: RKLAVYWSTYKRSR (SEQ ID NO: 1).
|
|
WO/2024/052947A1 |
The invention concerns a method, and a device that can implement this method, adapted to obtain adipose based compounds, of selectively variable particle sizes, distinguished by high levels of purity and by high concentrations of viable ...
|
|
WO/2024/052918A1 |
The present invention provides an isolated DNA molecule including at least a first nucleic acid sequence encoding a first protein and at least a second nucleic acid sequence encoding a second protein, wherein the first protein and the se...
|
|
WO/2024/054874A1 |
The use of IL-2Rβγc agonist peptides in cell manufacturing is disclosed. The IL-2Rβγc agonist peptides can facilitate the selective grow th of immune cell populations. Culture media comprising the IL-2Rβγc agonist peptides, methods...
|
|
WO/2024/054979A1 |
The present disclosure is directed to a genetic construct for performing loopable translation, a kit comprising the genetic construct, and a method of producing biomaterials comprising a highly repetitive protein by use of the genetic co...
|
|
WO/2024/053721A1 |
[Problem] To provide a therapeutic for spinal cord injury, especially severe spinal cord injury, from the acute phase to the subacute phase, the conventional treatment of which has been difficult. [Solution] A therapeutic for spinal cord...
|
|
WO/2024/051096A1 |
The present invention belongs to the technical field of molecular biology. Provided are an anti-CD40 nanobody, and a preparation method therefor and the use thereof. The provided anti-CD40 nanobody has three unique complementarity determ...
|
|
WO/2024/051751A1 |
Disclosed herein are anti-CD123 nanobodies, a chimeric antigen receptor, and use thereof. The nanobodies are VHH01 and VHH02. The nanobodies VHH01 and VHH02 both have good affinity and specificity for CD123. A chimeric antigen receptor a...
|
|
WO/2024/054627A1 |
Living tissue substrates (LTSs) are provided for diagnosing a tumor or screening for a therapeutic for a tumor are provided. Methods and systems for diagnosing a tumor or screening for a therapeutic for a tumor are provided, and can incl...
|
|
WO/2024/051855A1 |
A nucleic acid construct and use thereof in an IVTT system. Specifically provided is a nucleic acid construct. The nucleic acid construct has a structure of formula (I): Z1-Z2-Z3-Z4-Z5 (I). In the formula, Z1-Z5 are elements for constitu...
|
|
WO/2023/077029A9 |
The invention provides single-cell analysis using combined DNA sequencing of genomic DNA, which is performed to determine whether a segment of foreign DNA has been integrated. Individual cells are encapsulated with reagents, including pr...
|
|
WO/2024/052913A1 |
Provided herein is a composition comprising a hydrogel covalently bound to a functional moiety, wherein the hydrogel comprises a cross linkable biopolymer and a first cell population; the cross linkable biopolymer is at least partially c...
|
|
WO/2024/055043A2 |
Disclosed is minimal essential media for culturing induced human pluripotent stem cells (iPSCs), methods for preparing the media, and methods of using the media.
|
|
WO/2024/054631A1 |
Presented herein are compositions and methods involving mitochondrial organelle transplantation for use in the treatment of traumatic brain injury (TBI), e.g., mild traumatic brain injury (mTBI), in a subject.compositions and methods for...
|
|
WO/2024/055018A1 |
The present invention provides methods for preparing expanded tumor infiltrating lymphocytes (TILs) having reduced expression of PD-1 and TIGIT using sequential electroporation of two TALEN systems targeting PD-1 and TIGIT. Such TILs fin...
|
|
WO/2024/055002A1 |
Provided are a fusion protein comprising a mutated kinetochore protein and dCas9. The fusion protein is used in conjunction with guide RNAs target the fusion protein to a location of kinetochore assembly on a centromere such that the fus...
|
|
WO/2024/054939A1 |
This disclosure provides reagents and methods for producing NK progenitor cells, NK cells, megakaryocytes and CAR derivatives thereof from hematopoietic stem cells. Pharmaceutical compositions comprising NK progenitor cells produced by t...
|
|
WO/2024/050797A1 |
The present application relates to a multispecific antibody simultaneously targeting BCMA, GPRC5D and CD3, and a use thereof in the treatment of diseases such as tumors.
|
|
WO/2024/050638A1 |
Provided herein compositions and methods including bioprinted tissue fibers comprising precisely patterned cancerous and non-cancerous cells that are capable of recapitulating a desired tumor microenvironment in vitro. The subject tissue...
|
|
WO/2024/053585A1 |
The purpose of the present invention is to provide a method for expressing a desired substance at a high level in a plant. Provided are: a method for producing a plant having suppressed resistance to a pathogen, the method comprising s...
|
|
WO/2024/050645A1 |
This disclosure relates to laboratory devices and systems, methods of use, and methods of manufacture. Laboratory devices of this disclosure include a chamber or receptacle, and may also include one or more ports fluidically connected to...
|
|
WO/2024/053406A1 |
Research on methods for selective differentiation induction from pluripotent stem cells to small intestine epithelium-like cells is underway. The present invention provides an excellent highly functional small intestine epithelium-like c...
|
|
WO/2024/052931A1 |
A cell culture protocol for obtaining neural progenitor cells from induced pluripotent stem cells is described. Also described are a pharmaceutical composition and a medicament containing the neural progenitor stem cells for use in the t...
|
|
WO/2024/050923A1 |
Provided is a neuronal transfection method, comprising the following steps: 1) culturing adipocytes to obtain standardized adipose-derived exosomes; 2) packaging genetic material into isolated adipose-derived exosomes; and 3) co-culturin...
|
|
WO/2024/054564A2 |
MicroOrganoSpheres (MOS) generated using cells from multiple myeloma bone marrow biopsies are provided herein, as are methods and materials for making and using such MOS.
|
|
WO/2024/051022A1 |
The present invention relates to an HEK293 monoclonal cell population culturing method. By means utilizing a first culturing medium and a second culturing medium to culture HEK293 cells, steps from monoclonal plating to obtaining a HEK29...
|
|
WO/2024/053550A1 |
The present invention addresses the problem of providing a method for, when a plurality of DNAs encoding the same or similar proteins are present, modifying the plurality of DNAs using TALE. More specifically, the present invention relat...
|
|
WO/2024/054527A1 |
A method of treating or preventing central nervous system cancer in a subject in need thereof is described. The method includes administering to the subject a therapeutically effective amount of myeloid cells modified to express interleu...
|
|
WO/2024/054521A1 |
Provided herein are methods and compositions for identifying α-synuclein aggregation inhibitors. Also provided are methods of use of the α -synuclein aggregation inhibitors; the methods include methods of inhibition the formation of Le...
|
|
WO/2024/052434A1 |
The present invention relates to a SoxB1 factor variant comprising (a) the HMG (high-mobility group) domain of any one of the amino acid sequences of SEQ ID NOs: 1 to 3, wherein the amino acid alanine at position 61 of the HMG-domain is ...
|
|
WO/2024/053519A1 |
Disclosed are a kit for diagnosing Alzheimer's disease and a pharmaceutical composition for treating Alzheimer's disease that use EDIL3 or a nucleic acid that encodes EDIL3 as an indicator or a target.
|
|
WO/2024/054904A1 |
The present disclosure provides, in some aspects, humanized immunodeficient mouse models that support long-term engraftment and function of human T cells, natural killer cells, and myeloid cells, without the need for conditioning.
|
|
WO/2024/053648A1 |
The present invention provides candidate molecules for constituent components of various lipid nanoparticles. The present invention pertains to a C-glycoside glycolipid compound represented by formula (I) or formula (II), a lipid nanop...
|
|
WO/2024/053719A1 |
One purpose of the present invention is to provide an antibody against coronavirus (SARS-CoV-2) variants. Another purpose of the present invention is to provide a medicinal composition against coronavirus infections, the composition bein...
|
|
WO/2024/055017A1 |
The present invention provides methods for preparing expanded tumor infiltrating lymphocytes (TILs) having reduced expression of PD-1 and TIGIT using sequential electroporation of two TALEN systems targeting PD-1 and TIGIT. Such TILs fin...
|
